[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hanneke W. M. van Laarhoven\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100555992",false,"NCT06519292","Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer","ITHACA","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of the following tumor types, any stage: esophageal, gastric or junction cancer, colorectal cancer, non-small cell lung carcinoma, melanoma, renal cell carcinoma\n* Prior to start of new therapy (i.e. immune checkpoint inhibitor, chemotherapy or follow-up in case of esophageal cancer)\n* Age ≥ 50 years\n\nExclusion Criteria:\n\n* ICI therapy in previous 12 months\n* Suspected or confirmed viral, fungal, or bacterial infectious disease\n* Use of immunosuppressive therapy prior to ICI start\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Known allergy to iodinated contrast agents\n* Atrial fibrillation","ALL","50 Years",{"count":18,"type":19},214,"ESTIMATED","OBSERVATIONAL","Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system in the body. Recently, concerns have also risen about cardiovascular effects of ICI. Retrospective studies showed an 4-5 times increased risk of developing an arterial thromboembolic event.\n\nThe mechanisms driving the ICI-associated risks of arterial thromboembolic events such as myocardial infarction and stroke, are unclear. Since the risk of a thromboembolism appears to be increased already during the first months after initiation of ICI, immune-related hypercoagulability or (autoimmune) antiphospholipid antibodies may play a role, but data to support this are lacking. The longer-term risk of arterial thromboembolism may be predominantly driven by (accelerated) atherosclerosis, a chronic low-grade inflammatory disease of the larger arteries. Therefore, this study evaluates the effect of ICI on progression of coronary non-calcifid plaque volume by using computed tomography angiography (CCTA).",[23,24,25,26,27,28,29],"Cardiovascular Diseases","Arterial Thrombosis","Myocardial Infarction","Stroke","Coronary Artery Disease","Atherosclerosis","Cancer",[31,32,33],"immune checkpoint inhibitors","cardiovascular disease","atherosclerosis","RECRUITING","2025-05-20",{"date":37,"type":38},"2025-05-22","ACTUAL",{"date":40,"type":38},"2023-01-25",{"date":42,"type":19},"2025-12-31",{"name":44,"class":45},"Hanneke W. M. van Laarhoven","OTHER",""]